MedElevator Войти в исследования
← Поиск публикаций

DOI 10.12659/ajcr.948566

Медицинская библиотека · The American journal of case reports · 2025

Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies.

Wu Li-Na, Zeng Zhi-Gui, Liu Jing-Yi, Wei Lin, Tan Yu-Le, Xie Fu-Xiao, Zhu Zhi-Jun, Sun Li-Ying

СтатьяКлинический случайПеревод в очереди

Аннотация

BACKGROUND EBV-associated smooth muscle tumors (EBV-SMTs) are rare malignancies in pediatric transplant recipients under chronic immunosuppression, with fewer than100 cases reported globally. Diagnosis is challenging due to nonspecific imaging findings and overlapping features with other post-transplant malignancies, necessitating histopathological confirmation. This underscores the need for heightened clinical suspicion in high-risk cohorts. CASE REPORT Here, we present a pediatric case from our liver transplant (LT) center involving a patient who developed both post-transplant lymphoproliferative disorder (PTLD) and EBV-SMT following liver transplantation. Clinical data and comprehensive treatment details of this rare case were retrospectively reviewed. The patient, diagnosed with a congenital bile acid synthesis defect, underwent liver transplantation at the age of 5 months. Pre-transplant screening confirmed that both the donor and recipient were negative for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections. However, EBV DNA became detectable in peripheral blood at 22.5 months after transplantation and showed a progressive increase over time. At 30.9 months after LT, PTLD and hepatic EBV-SMT were simultaneously diagnosed through histopathological examination. Treatment strategies included stepwise immunosuppression reduction, administration of rituximab targeting PTLD, and subsequent sirolimus therapy for EBV-SMT and surgical resection of the liver and splenic tumor. This multidisciplinary approach successfully achieved complete remission. CONCLUSIONS EBV-SMT necessitates multidisciplinary management balancing immunosuppression with targeted therapies. mTOR inhibitors are a strategic option for concurrent rejection prevention and tumor control. Sirolimus, a mechanistic target of rapamycin (mTOR) inhibitor, demonstrates promise by simultaneously preventing rejection and inhibiting tumor progression.

Для цитирования: Wu Li-Na, Zeng Zhi-Gui, Liu Jing-Yi, Wei Lin, Tan Yu-Le, Xie Fu-Xiao, Zhu Zhi-Jun, Sun Li-Ying. Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies.. The American journal of case reports. 2025. DOI: 10.12659/ajcr.948566.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.